A5048740921- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Hemostasis and retained surgical items
- Blood donation and transfusion practices
- Cancer-related gene regulation
- Chronic Myeloid Leukemia Treatments
- Hemoglobinopathies and Related Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood transfusion and management
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood groups and transfusion
- Case Reports on Hematomas
- Mast cells and histamine
- COVID-19 and healthcare impacts
- Periodontal Regeneration and Treatments
- Blood properties and coagulation
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Iron Metabolism and Disorders
- PARP inhibition in cancer therapy
- COVID-19 Clinical Research Studies
- Heterotopic Ossification and Related Conditions
KPJ Ampang Puteri Specialist Hospital
2021-2022
Ministry of Health
2021
Institut Gustave Roussy
2017
Creative Commons
2016
Kuala Lumpur Sports Medicine Centre
2014-2016
National Blood Transfusion Service
2015
BackgroundVatreptacog alfa, a recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions and 99% identity to native FVIIa, was developed improve the treatment of hemophilic patients inhibitors.ObjectivesTo confirm safety assess efficacy vatreptacog alfa in treating bleeding episodes inhibitors.Patients methodsIn this international, multicenter, randomized, double‐blind, active‐controlled, crossover, confirmatory phase III trial (adept™2) hemophilia A or B inhibitors, bleeds...
Turoctocog alfa pegol (N8-GP, Novo Nordisk, Bagsværd, Denmark), an extended half-life glycoPEGylated recombinant factor VIII (rFVIII), is being developed for prophylaxis and treatment of bleeds in haemophilia A patients. pathfinder™5 a multinational, open-label, single-arm trial to assess safety, efficacy pharmacokinetics N8-GP paediatric (<12 years), previously treated Boys with severe (<1 % FVIII), no history inhibitors FVIII products (>50 exposure days [ED] patients aged 0-5 years...
ABSTRACT Introduction Clinical trials and real‐world evidence have demonstrated the efficacy safety of rVIII‐SingleChain in previously treated patients with haemophilia A. Aim To investigate untreated (PUPs). Methods In an open‐label, phase 3, extension study, PUPs severe A (FVIII <1%) received prophylactically or on‐demand. The primary endpoints were incidence high‐titre (HT) inhibitor formation to FVIII, treatment success for major bleeding episodes annualised spontaneous rate (AsBR)....
Introduction Surgery in patients with haemophilia B carries a high risk of excessive bleeding and requires adequate haemostatic control until wound healing. Nonacog beta pegol, long‐acting recombinant glyco PEG ylated factor IX ( FIX ), was used the perioperative management undergoing major surgery. Aim To evaluate efficacy safety nonacog pegol who undergo Methods This an open‐label, multicentre, non‐controlled surgery trial aimed at assessing peri‐ postoperative 13 previously treated B. All...
Background The paradigm ™ 2 and 4 phase 3 clinical trials investigated the safety efficacy of nonacog beta pegol, a recombinant glyco PEG ylated factor IX ( FIX ) with extended half‐life, in previously treated haemophilia B patients. Aim These post hoc analyses bleeding patterns target joints. Methods Patients randomized to 40 or 10 IU kg −1 once weekly prophylaxis who had at least one joint were included. Baseline demographics disease‐specific data collected. Bleeding assessed, an...
N8-GP (turoctocog alfa pegol; Esperoct® , Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated human recombinant factor VIII with half-life of ~1.6-fold standard FVIII products. pathfinder2 (NCT01480180) was multi-national, open-label trial in previously treated adolescent and adult patients severe hemophilia A.We report end-of-trial efficacy safety from pathfinder2.pathfinder2 main phase extension part 1 results have been reported. During 2, could switch prophylaxis 50 IU/kg every...
Introduction Recombinant factor IX fusion protein (r ‐ FP ) has been developed to improve the pharmacokinetic ( PK profile of FIX ), allowing maintenance desired activity between injections at extended intervals, ultimately optimizing haemophilia B treatment. Aim To determine efficacy and safety r in perioperative setting. Methods Subjects were adult paediatric patients with severe moderately ≤ 2%) participating three Phase III clinical trials undergoing a surgical procedure. profiles...
During factor VIII prophylaxis for severe hemophilia A, bleeding risk increases with time when activity is below 1%. Maintaining trough above 1% does not protect all patients from bleeding. The relationship between during and has been thoroughly studied. We investigated annualized rate spontaneous bleeds prophylaxis. A population pharmacokinetic model derived three clinical trials was combined dosing data bleed information patient diaries. Each patients' on divided into five categories of...
rVIII-SingleChain is a recombinant single-chain factor VIII used to treat people with hemophilia A.
Long-acting recombinant factor IX (FIX) products may simplify the surgical treatment of haemophilia B patients. The impact rIX-FP, a FIX fused to albumin, on consumption and management was assessed in patients with B.Male patients, ≤65 years old severe (FIX activity ≤2%) requiring non-emergency surgery were enrolled substudy PROLONG-9FP. Dosing based World Federation Hemophilia guidelines patients' pharmacokinetics. Haemostatic efficacy 4-point scale. rIX-FP safety monitored throughout...
Von Willebrand disease (vWD) is an inherited hemostatic disorder that affects the hemostasis pathway. The worldwide prevalence of vWD estimated to be 1% general population but only 0.002% in Malaysia.Our present paper has been written disclose statistical counts on number cases reported from 2011 2013.This article based sociodemographic data, diagnoses and laboratory findings Malaysia. A total 92 patients were have Malaysia 2013.Sociodemographic-analysis revealed 60% females, 63% Malay...
: Haemophilia treatment guidelines advocate early home-based of acute bleeds. In the ADEPT2 trial, data were collected on home bleeds with recombinant activated factor VII (rFVIIa) in haemophilia patients inhibitors and self-reported bleeding-related symptoms. A total 93% all bleeds, 91.5% joint treated successfully one to three doses 90 μg/kg rFVIIa. However, some self-administered additional haemostatic medication (AHM) up 48 h after first rFVIIa treatment. The aim this trial was...
INTRODUCTION: Transfusion of blood and components among obstetrics patients is a common practice but they are not without risks. This study aims to determine crossmatch transfusion ratio (C:T ratio) assess the factors that influence red cells (RBC) in single tertiary hospital. MATERIAL AND METHODS: was retrospective cohort RBC requests with data collected from 350 patients. The were grouped into either received or did receive transfusion. Demographics clinical characteristics analyzed using...